Cervomed to deliver oral presentation at the 8th international lewy body dementia conference

Topline data from the rewind-lb phase 2b study on track for december 2024 detailed safety and efficacy data from rewind-lb phase 2b study to be featured in an oral presentation at the ilbdc conference in january 2025 boston, oct. 29, 2024 (globe newswire) -- cervomed inc. (nasdaq: crvo), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its completed rewind-lb phase 2b clinical trial of neflamapimod in dementia with lewy bodies (dlb) at the eighth international lewy body dementia conference (ilbdc) taking place on january 29-31, 2025 in amsterdam, the netherlands. “as we await topline results from the rewind-lb phase 2b trial in dlb, we are extremely encouraged by the scientific community's interest in the data and pleased to have an opportunity to present them at the leading scientific conference dedicated to lewy body dementia,” said john alam, md, chief executive officer of cervomed.
CRVO Ratings Summary
CRVO Quant Ranking